 This study is designed to evaluate the efficacy and safety of tofacitinib modified release formulation 11mg QD versus tofacitinib modified release formulation plus continued methotrexate treatment in subjects with moderate to severe rheumatoid arthritis who are insufficiently responding to their stable dose of methotrexate treatment. 